Fig. 1 · Structure

Documents & Downloads

FR 180204

Cat. No. A14119 CAS 865362-74-9

ERK inhibitor

FR 180204 is a novel and selective inhibitor of extracellular signal-regulated kinase (ERK), which may be a potential new therapy for rheumatoid arthritis.

In Stock

Publications for FR 180204

2 publications citing this product

  1. Sergey A Dyshlovoy, .et al. , Sci Rep, 2020, Aug 6;10(1):13178 PMID: 32764580
  2. Dyshlovoy SA, .et al. , Proteomics, 2017, Jun;17(11) PMID: 28445005

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
ERK2 Ki 0.14 μM
ERK1 Ki 0.31 μM

In Vitro Studies

In 22Rv1 prostate cancer cells, FR180204 combined with monanchoxymycalin C produced condition-dependent MTT viability effects: six tested pairs were synergistic, while two lower-concentration pairs were antagonistic. These combination results do not establish single-agent anticancer selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Condition-dependent combination effects with monanchoxymycalin C

Cell-based study · Human 22Rv1 prostate cancer cells [1]

Eight MomC–FR180204 pairs showed two antagonistic and six synergistic combination indices. The first two low-concentration pairs were antagonistic; synergy cannot be generalized across the tested matrix. This is a metabolic viability combination assay, not a biochemical ERK potency measurement or proof of single-agent anticancer selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT-derived combination effect: MomC 0.625 µM + FR180204 6.25 µMFraction affected; combination index Fa = 0.562; CI = 1.41159[1]
MTT-derived combination effect: MomC 1.25 µM + FR180204 12.5 µMFraction affected; combination index Fa = 0.584; CI = 2.06078[1]
MTT-derived combination effect: MomC 2.5 µM + FR180204 25.0 µMFraction affected; combination index Fa = 0.689; CI = 0.83997[1]
MTT-derived combination effect: MomC 5.0 µM + FR180204 50.0 µMFraction affected; combination index Fa = 0.858; CI = 0.05468[1]
MTT-derived combination effect: MomC 0.625 µM + FR180204 12.5 µMFraction affected; combination index Fa = 0.656; CI = 0.36643[1]
MTT-derived combination effect: MomC 1.25 µM + FR180204 25.0 µMFraction affected; combination index Fa = 0.666; CI = 0.62870[1]
MTT-derived combination effect: MomC 2.5 µM + FR180204 50.0 µMFraction affected; combination index Fa = 0.815; CI = 0.08726[1]
MTT-derived combination effect: MomC 5.0 µM + FR180204 100.0 µMFraction affected; combination index Fa = 0.898; CI = 0.01950[1]

Literature-Reported Treatment Conditions

Treatment concentration
FR180204 6.25–100.0 µM with MomC 0.625–5.0 µM; exact pairs in measurements
Exposure duration
1 h inhibitor/vehicle pretreatment, then 48 h after MomC addition
Method
MTT viability followed by Chou–Talalay analysis; 10% FBS/RPMI medium
Vehicle
Equal amount of DMSO in control cells
Co-treatment
Monanchoxymycalin C (MomC); single agents were considered in combination analysis
Reported limits
No tested FR180204 salt, lot, purity, or final vehicle percentage specified in reviewed methods. Triplicate statement does not distinguish biological from technical replicates.
Methods and source locations

Compound reported in the paper: FR180204; Compound label in the paper: ERK1/2 inhibitor

Applies to the named research compound in this cell-line combination experiment; no salt conversion or Adooq lot equivalence.

Figure 6b (image labels); Supplementary Table S3; Methods: Determination of drug combination effects, Cell lines and culture conditions, Reagents and antibodies

MTT-derived combination effect: MomC 0.625 µM + FR180204 6.25 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis

MTT-derived combination effect: MomC 1.25 µM + FR180204 12.5 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis

MTT-derived combination effect: MomC 2.5 µM + FR180204 25.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis

MTT-derived combination effect: MomC 5.0 µM + FR180204 50.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis

MTT-derived combination effect: MomC 0.625 µM + FR180204 12.5 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis

MTT-derived combination effect: MomC 1.25 µM + FR180204 25.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis

MTT-derived combination effect: MomC 2.5 µM + FR180204 50.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis

MTT-derived combination effect: MomC 5.0 µM + FR180204 100.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis

In Vivo Studies

In PS1APP mice, hippocampal delivery of FR180204 increased interstitial amyloid-β and prevented the usual amyloid-β reduction during high NMDA stimulation. The 100 µM concentration refers to the microdialysis perfusate; actual brain concentration was uncertain. This local pathway experiment does not establish systemic brain exposure or therapeutic benefit. [2]

Local ERK-pathway inhibition alters hippocampal interstitial amyloid-β

Animal study · Young PS1APP hemizygous mice (APP/PS1ΔE9); Methods 2.5–3.5 months, Results approximately 3–4 months; equal males and females per experiment [2]

Local FR180204 increased basal hippocampal interstitial Aβ and reversed the usual Aβ-lowering response to high NMDA stimulation. This pharmacological pathway experiment bypassed the blood–brain barrier and does not establish systemic brain exposure or therapeutic benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Change in hippocampal ISF Aβ after FR180204 alonePercent increase from each mouse baseline 42.4 ± 8.1%; p < 0.01; n = 5–6 per group (caption groups inhibitor experiments); mean ± SEM[2]
ISF Aβ response to 40 µM NMDA in the presence of FR180204Percent increase from basal levels 210.5 ± 47.8%; mean ± SEM[2]

Conditions shared by the study groups

Route
Local hippocampal infusion by reverse microdialysis; bypasses the blood–brain barrier.
Frequency
Continuous perfusion during the indicated treatment interval.
Vehicle
Artificial CSF containing 4% bovine serum albumin (microdialysis perfusion buffer).
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
FR180204 alone
FR180204 100 µM in microdialysis perfusate.
Each mouse’s preceding 6 h baseline; parallel vehicle-only group in Figure 5C–D.Hippocampal ISF Aβ increased by 42.4 ± 8.1% from baseline; p < 0.01; mean ± SEM (existing measurement fr_abeta_alone).[2]
FR180204 followed by NMDA coadministration
FR180204 100 µM in perfusate; NMDA 40 µM added during ongoing FR180204 perfusion.
Each mouse’s preceding 6 h baseline; FR180204-alone and vehicle ± 40 µM NMDA groups in Figure 5C–D.Hippocampal ISF Aβ increased by 210.5 ± 47.8% from basal levels; mean ± SEM (existing measurement fr_abeta_nmda). Vehicle plus NMDA decreased Aβ; Figure 5D marks the FR180204 plus NMDA group as different from FR180204 alone.[2]
FR180204 alone
Model: Young PS1APP hemizygous mice (APP/PS1ΔE9); Methods 2.5–3.5 months, Results approximately 3–4 months; equal males and females per experiment
Treatment course: FR180204 from 0 to 12 h in Figure 5C; caption reports inhibitor-alone response by 12 h.
Reported limits: Nominal perfusate concentration is not an administered mass dose or measured brain concentration. Actual tissue concentration is uncertain. Caption groups inhibitor experiments as n = 5–6 per group without assigning an exact FR180204 group size; no salt, lot or analytical authentication reported.
FR180204 followed by NMDA coadministration
Model: Young PS1APP hemizygous mice (APP/PS1ΔE9); Methods 2.5–3.5 months, Results approximately 3–4 months; equal males and females per experiment
Treatment course: FR180204 from 0 h; NMDA added at 6 h and coadministered through 12 h in Figure 5C.
Reported limits: Nominal perfusate concentration is not an administered mass dose or measured brain concentration. Actual tissue concentration is uncertain. Caption groups inhibitor experiments as n = 5–6 per group without assigning an exact FR180204 group size; no salt, lot or analytical authentication reported.
Methods and source locations

Compound reported in the paper: FR180204; Compound label in the paper: ERK inhibitor

Local mouse hippocampal pharmacology only; cannot infer Adooq lot validation, systemic dosing, brain penetration or clinical efficacy.

Figure 5C–D and caption; Results: ERK signaling is required for NMDA-dependent depression of ISF Aβ levels; Methods: Animals, Compounds, In vivo microdialysis, Aβ ELISA, Statistics

Change in hippocampal ISF Aβ after FR180204 alone: Reverse microdialysis and Aβ sandwich ELISA; baseline mean over 6 h preceding treatment — Figure 5C–D and caption; In vivo microdialysis methods

ISF Aβ response to 40 µM NMDA in the presence of FR180204: Sequential reverse microdialysis; Figure 5C–D. This is an increase relative to baseline, not percent of baseline. — Figure 5C–D and caption; ERK signaling Results

FR180204 alone · Figure 5C–D image and caption; Results: ERK signaling is required for NMDA-dependent depression of ISF Aβ levels; Methods: Animals, Compounds, In vivo microdialysis, Statistics

FR180204 followed by NMDA coadministration · Figure 5C–D image and caption; Results: ERK signaling is required for NMDA-dependent depression of ISF Aβ levels; Methods: Animals, Compounds, In vivo microdialysis, Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 865362-74-9
Applications ERK inhibitor
Formula C18H13N7
Molecular Weight 327.34
SMILES
C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=CC5=C(NN=C5N=N4)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 57 mg/mL (174.13 mM)
Water Insoluble
Ethanol Warmed: 2 mg/mL (6.1 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Dyshlovoy SA, Kaune M, Kriegs M, et al. Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer properties. Scientific reports (2020). PMID: 32764580 DOI: 10.1038/s41598-020-69751-z Source material
  2. [2] Verges DK, Restivo JL, Goebel WD, et al. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo. The Journal of neuroscience : the official journal of the Society for Neuroscience (2011). PMID: 21813692 DOI: 10.1523/jneurosci.0607-11.2011 Source material

Publications

2 publications citing this product

  1. Sergey A Dyshlovoy, .et al. , Sci Rep, 2020, Aug 6;10(1):13178 PMID: 32764580
  2. Dyshlovoy SA, .et al. , Proteomics, 2017, Jun;17(11) PMID: 28445005

Added to your cart

View Cart Checkout
Loading...